.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin caused improved progression-free as well as total survival, leading to FDA commendation and also a brand new treatment option for individuals.